Research programme: prolyl hydroxylase inhibitors - FibroGen

Drug Profile

Research programme: prolyl hydroxylase inhibitors - FibroGen

Alternative Names: FG 4497; FG 4539; Research programme: HIF prolyl hydroxylase inhibitors - FibroGen

Latest Information Update: 26 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator FibroGen
  • Class Small molecules
  • Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cerebral ischaemia; Ischaemia; Kidney disorders; Obesity; Sickle cell anaemia; Stroke; Wounds

Most Recent Events

  • 27 Feb 2018 Preclinical development is ongoing in USA
  • 12 Dec 2016 The European Patent Office revokes two patents for HIF-related technology in Europe
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cerebral-ischaemia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top